<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01062971</url>
  </required_header>
  <id_info>
    <org_study_id>SOPHIA-PRO-122</org_study_id>
    <nct_id>NCT01062971</nct_id>
  </id_info>
  <brief_title>Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide</brief_title>
  <official_title>Comparative Clinical Study of The Safety And Efficacy of A New Fixed-Combination of Timolol-Brimonidine-Dorzolamide In Patients With Open Angle Glaucoma Or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare intraocular pressure lowering effectiveness of a new fixed combination drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentric, double blind and prospective clinical study. We will include
      patients with confirmed diagnosis of primary open-angle glaucoma and/or ocular hypertension,
      with intraocular pressure (IOP) ranging between 21 and 31 mm Hg. Patients will be randomly
      divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2%
      brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia,
      Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination
      (Cosopt®, MSD Laboratories, USA). Patients will receive 1 drop twice a day of either
      formulations and were examined at days 2, 7, 15, 30, 60, and 90 after initiation of
      treatment. The primary objective is to compare the efficacy of both formulations, estimated
      as a decrease in IOP. A Goldmann applanation tonometer will be used for IOP determination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the intraocular pressure throughout the study period. To evaluate the reduction of intraocular pressure in both groups of treatment.</measure>
    <time_frame>basal, and days 1, 2,7,14,15, 30 and 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To follow and compare the safety parameters throughout the study period in both groups of treatment.</measure>
    <time_frame>basal, and day 1,2,7,15,30 y 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IOP Dorzolamide-Timolol-Brimonidine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IOP dorzolamide-timolol group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dorzolamide-timolol-brimonidine</intervention_name>
    <description>Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Krytantek Ofteno</other_name>
    <other_name>Cosopt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects of either sex and any race with open-angle glaucoma or ocular
             hypertension;

          -  Visual acuity of 20/40 to 20/80 or better (Snellen equivalent).

        Exclusion Criteria:

          -  Clinically relevant ophthalmic or systemic conditions may be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo M Baiza-Duran, MD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department. Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de la Visión. Hospital Universitario La Carlota. Universidad de Montemorelos</name>
      <address>
        <city>Montemorelos</city>
        <state>Nuevo Leon</state>
        <zip>67500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>February 3, 2010</lastchanged_date>
  <firstreceived_date>February 2, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Leopoldo Baiza-Duran</name_title>
    <organization>Laboratorios Sophia S.A de C.V.</organization>
  </responsible_party>
  <keyword>Open-angle glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>POAG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
